CBD for Endometriosis: Preclinical Promise but Not Enough Evidence to Recommend

While lab studies show cannabis-based products may affect endometriosis mechanisms, clinical evidence is too weak to recommend them, and potential harms including cannabis use disorder and psychosis should be considered.

Mistry, Megha et al.·Journal of minimally invasive gynecology·2022·Moderate EvidenceSystematic Review
RTHC-04067Systematic ReviewModerate Evidence2022RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Systematic Review
Evidence
Moderate Evidence
Sample
N=41

What This Study Found

Of 264 articles screened, 41 were included. Most evidence comes from lab studies simulating cannabis effects on endometriosis models, with some showing benefit but conflicting results. Few human studies exist, mostly surveys with bias. UK national guidance cannot currently recommend cannabis for endometriosis due to lack of clear evidence.

Key Numbers

264 articles screened; 41 included; most evidence preclinical; UK guidance does not recommend cannabis for endometriosis

How They Did This

Systematic review searching PubMed, EMBASE, Cochrane, and gray literature for studies on cannabis-based products and endometriosis or chronic pelvic pain.

Why This Research Matters

Endometriosis affects 10% of reproductive-age women and current treatments often impair fertility. Cannabis-based products are being explored as alternatives, but the evidence base is critically thin.

The Bigger Picture

Many endometriosis patients are already self-medicating with cannabis. The gap between patient demand and clinical evidence highlights the urgent need for randomized controlled trials.

What This Study Doesn't Tell Us

Predominantly preclinical evidence. Human studies limited to biased surveys. Lab results may not translate to clinical effectiveness.

Questions This Raises

  • ?Would topical or vaginal cannabinoid formulations be more effective for pelvic pain than systemic administration?
  • ?Can endometriosis-specific clinical trials be prioritized?

Trust & Context

Key Stat:
UK guidance: insufficient evidence to recommend
Evidence Grade:
Systematic review finding predominantly preclinical evidence with very few human studies, most of which are biased surveys.
Study Age:
Published in 2022
Original Title:
Cannabidiol for the Management of Endometriosis and Chronic Pelvic Pain.
Published In:
Journal of minimally invasive gynecology, 29(2), 169-176 (2022)
Database ID:
RTHC-04067

Evidence Hierarchy

Meta-Analysis / Systematic ReviewCombines many studies into one answer
This study
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal Study

Analyzes all available research on a topic using a structured method.

What do these levels mean? →

Frequently Asked Questions

Does CBD help with endometriosis?

Lab studies show some promise, but clinical evidence is too thin to make recommendations. The review noted that human studies are mostly surveys with significant bias, and UK national guidance does not support prescribing cannabis for endometriosis.

What are the risks of using cannabis for endometriosis?

The review highlighted potential harms including cannabis use disorder, psychosis risk, and mood disturbances, noting these should be weighed against unproven benefits.

Read More on RethinkTHC

Cite This Study

RTHC-04067·https://rethinkthc.com/research/RTHC-04067

APA

Mistry, Megha; Simpson, Paul; Morris, Edward; Fritz, Ann-Katrin; Karavadra, Babu; Lennox, Carole; Prosser-Snelling, Ed. (2022). Cannabidiol for the Management of Endometriosis and Chronic Pelvic Pain.. Journal of minimally invasive gynecology, 29(2), 169-176. https://doi.org/10.1016/j.jmig.2021.11.017

MLA

Mistry, Megha, et al. "Cannabidiol for the Management of Endometriosis and Chronic Pelvic Pain.." Journal of minimally invasive gynecology, 2022. https://doi.org/10.1016/j.jmig.2021.11.017

RethinkTHC

RethinkTHC Research Database. "Cannabidiol for the Management of Endometriosis and Chronic ..." RTHC-04067. Retrieved from https://rethinkthc.com/research/mistry-2022-cannabidiol-for-the-management

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.